Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

被引：7
|
作者：
Miron, Benjamin [1 ]
Geynisman, Daniel M. [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
EUROPEAN UROLOGY | 2022年 / 82卷 / 04期
关键词：
CHEMOTHERAPY; CISPLATIN; MULTICENTER;
D O I：
10.1016/j.eururo.2022.05.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：374 / 376
页数：3
相关论文
共 50 条
  • [11] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    Mansinho, Andre
    Cruz, Andreia
    Marconi, Lorenzo
    Pinto, Cidalia
    Augusto, Isabel
    ADVANCES IN THERAPY, 2023, 40 (10) : 4134 - 4150
  • [12] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    André Mansinho
    Andreia Cruz
    Lorenzo Marconi
    Cidália Pinto
    Isabel Augusto
    Advances in Therapy, 2023, 40 : 4134 - 4150
  • [13] Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
    Rijavec, Erika
    Indini, Alice
    Ghidini, Michele
    Tomasello, Gianluca
    Cattaneo, Monica
    Barbin, Francesca
    Grossi, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 705 - 713
  • [14] Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma
    Lin, Jingwen
    Song, Xiaobing
    Fu, Wu
    You, Caicong
    Li, Na
    Liu, Maobai
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [15] Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC
    El-Ghazzi, Nathan
    Lavaud, Pernelle
    BULLETIN DU CANCER, 2021, 108 (03) : 231 - 233
  • [16] Reevaluating immunotherapy's potential in first-line metastatic urothelial carcinoma
    Castano-Amores, Celia
    Nieto-Gomez, Pelayo
    JOURNAL OF CHEMOTHERAPY, 2024,
  • [17] Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
    Tannir, Nizar M.
    Cho, Daniel C.
    Diab, Adi
    Sznol, Mario
    Bilen, Mehmet A.
    Balar, Arjun, V
    Grignani, Giovanni
    Puente, Erika
    Tang, Lily
    Chien, David
    Hoch, Ute
    Choudhury, Arkopal
    Yu, Danni
    Currie, Sue L.
    Tagliaferri, Mary A.
    Zalevsky, Jonathan
    Siefker-Radtke, Arlene O.
    Hurwitz, Michael E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [18] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    UROLOGIE, 2023, 62 (08): : 830 - 839
  • [19] Impact of renal impairment on first-line treatment in metastatic urothelial cancer
    Wakeling, S.
    Inderjeeth, A.
    Weickhardt, A. J.
    Lynam, J.
    Gibbs, P.
    O'Haire, S.
    Zlatic, K.
    Wong, S. S. L.
    Sengupta, S.
    Manohar, P.
    Zhang, A.
    Wong, L-M.
    Tran, B.
    Conduit, C. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1568 - S1569
  • [20] Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.
    Lyou, Yung
    Grivas, Petros
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean H.
    Quinn, David, I
    Petrylak, Daniel Peter
    Galsky, Matt D.
    Vaishampayan, Ulka N.
    De Giorgi, Ugo
    Gupta, Sumati
    Burris, Howard A., III
    Rearden, Jessica
    Andresen, Corina
    Wang, Hao
    Daneshmand, Siamak
    Bajorin, Dean F.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345